The estimated Net Worth of Jack Kaye is at least $524 Thousand dollars as of 13 June 2024. Mr. Kaye owns over 2,218 units of uniQure N.V stock worth over $35,560 and over the last 8 years he sold QURE stock worth over $232,635. In addition, he makes $255,810 as Non-Executive Independent Director at uniQure N.V.
Jack has made over 9 trades of the uniQure N.V stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 2,218 units of QURE stock worth $11,445 on 13 June 2024.
The largest trade he's ever made was exercising 27,174 units of uniQure N.V stock on 2 January 2024 worth over $148,642. On average, Jack trades about 1,655 units every 101 days since 2017. As of 13 June 2024 he still owns at least 6,501 units of uniQure N.V stock.
You can see the complete history of Mr. Kaye stock trades at the bottom of the page.
Jack L. Kaye CPA serves as Non-Executive Independent Director of the Company. Mr. Kaye has also served as Chairman of the Audit Committee of Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) from 2006 to 2016 and is currently chairman of the Audit Committee and a member of the Compensation Committee of Dyadic International, Inc. (OTC: DYAI). Mr. Kaye began his career at Deloitte LLP, an international accounting, tax and consulting firm, in 1970, and was a partner in the firm from 1978 until May 2006. At Deloitte, he was responsible for servicing a diverse client base of public and private, global and domestic companies in a variety of industries. Mr. Kaye has extensive experience consulting with clients on accounting and reporting matters, private and public debt financings, SEC rules and regulations and corporate governance/Sarbanes-Oxley matters. Prior to retiring, Mr. Kaye served as Partner-in-Charge of Deloitte’s Tri-State Core Client practice, a position he held for more than 20 years. Mr. Kaye has a Bachelor of Business Administration from Baruch College and is a Certified Public Accountant.
As the Non-Executive Independent Director of uniQure N.V, the total compensation of Jack Kaye at uniQure N.V is $255,810. There are 10 executives at uniQure N.V getting paid more, with Matthew Kapusta having the highest compensation of $4,719,960.
Jack Kaye is 76, he's been the Non-Executive Independent Director of uniQure N.V since . There are no older and 15 younger executives at uniQure N.V.
Jack's mailing address filed with the SEC is C/O UNIQURE N.V., PAASHEUVELWEG 25A, AMSTERDAM, P7, 11058BP.
Over the last 8 years, insiders at uniQure N.V have traded over $35,572,573 worth of uniQure N.V stock. The most active insiders traders include Deventer Sander Van, Paula Soteropoulos, and William Lewis. On average, uniQure N.V executives and independent directors trade stock every 14 days with the average trade being worth of $37,634. The most recent stock trade was executed by Walid Abi Saab on 26 June 2024, trading 1,447 units of QURE stock currently worth $6,309.
uniqure is delivering on the promise of gene therapy - single treatments with potentially curative results. we are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with severe genetic diseases.
uniQure N.V executives and other stock owners filed with the SEC include: